Porphyrias, Hepatic
|
0.210 |
Biomarker
|
group |
RGD |
Hexachlorobenzene treatment on hepatic mitochondrial function parameters and intracellular coproporphyrinogen oxidase location.
|
19482825 |
2008 |
Porphyrias, Hepatic
|
0.210 |
GeneticVariation
|
group |
LHGDN |
Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias.
|
14669009 |
2004 |
Hypertensive disease
|
0.110 |
Biomarker
|
group |
BEFREE |
In a different set of 14-day Ang II-salt-treated rats, mini-osmotic pumps were used to infuse either a nonselective COX (cyclooxygenase) inhibitor ketorolac, L-PGDS inhibitor AT56, or DP1R inhibitor BWA868C to test the role of brain COX-PGD2-DP1R signaling in Ang II-salt hypertension.
|
31587572 |
2019 |
Hypertensive disease
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Apart from their anti-inflammatory action, COX inhibitors have gathered the interest of many scientists due to their potential use for the treatment and prevention of cancer.
|
31064095 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mechanism of differentiation-enhanced photodynamic therapy for cancer: upregulation of coproporphyrinogen oxidase by C/EBP transcription factors.
|
23686770 |
2013 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX inhibitors are widely used for analgesia and also have demonstrated activity for cancer prophylaxis.
|
23624019 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we find that the activation of Akt pathway in cancer cells is crucial for the pro-metastatic effect of COX-2<sup>+</sup> TAMs by regulating MMP-9 and EMT.
|
27994517 |
2016 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The COX proportional hazard model predicts that among these, the relative expression of circRNA_104916 and lymphatic metastatic status independently predict the prognosis of patients with cancer.
|
30844715 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, 6 prognosis related genes were selected out by COX regression analysis, TFCP2L1 related to cancer-stem cell, probably contributes to chemotherapy efficiency.
|
26228058 |
2015 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The SNPs in the COX genes may help us to evaluate the cancer risk of HCC.
|
28703354 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The COX pathway has been a target for pharmaceutical intervention in diseases with a high inflammatory component ranging from asthma and Alzheimer's to arthritis and cancer.
|
19390242 |
2009 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Two Cox genes have been cloned, and expression of Cox-2 mRNA and protein has been shown to be elevated in several human malignancies and in animal models of carcinogenesis.
|
11448905 |
2001 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since COX enzyme has been involved, with different mechanisms, in the development and progression of malignancies we decided to investigate the expression and localization of COX-1 and COX-2 in normal human oral mucosa and three different pathologies (hyperplasia, dysplasia and carcinoma) by immunohistochemistry and RT-PCR.
|
21478098 |
2010 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Impact of PLND on cancer specific survival (CSS), overall survival (OS) and progression-free survival (PFS) was analyzed using log-rank test and COX regression model.
|
28900840 |
2017 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
|
17691999 |
2007 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX inhibitors also alter the expression of a number of genes that influence cancer development.
|
16337272 |
2006 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aspirin's ability to act on multiple key metabolic and signaling pathways via inhibition of the cyclooxygenase (COX) enzyme, as well as through COX-independent mechanisms, makes it particularly relevant in the fight against cancer.
|
25842298 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first part of this review provides a survey of the development of both modified traditional NSAIDs (tNSAIDs) and COX inhibitors (coxibs) with reduced side effects for the treatment of inflammation and cancer.
|
26566186 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicate the functional role of the MIF-COX-p53 axis in inflammation and cancer at the genomic and proteomic levels in COX-2-ablated cells.
|
29247872 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their anti-inflammatory, analgesic, and antipyretic effects by reversibly or irreversibly acetylating COX isoforms, inhibiting downstream prostaglandins, and may have a chemopreventive role in malignancies, including skin cancer.
|
30523664 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclooxygenase (COX) enzymes, COX-1 and COX-2, play crucial roles in the pathogenesis of human malignancies.
|
20392831 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, patients with overexpressed IMP3 had a poorer prognosis (P<0.01); COX regression analysis revealed that the overexpression of IMP3, the tumor grade, tumor size and metastasis of GEP-NEN were each associated with the clinical outcomes.
|
28454409 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The data on the prognostic importance of COX expression in these tumours is inconsistent and conflicting.
|
24950702 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Many in vitro and in vivo studies on human and animal models have explained the mechanisms of the chemopreventive effect of COX inhibitors such as: induction of apoptosis, inhibition of neoplasia, angiogenesis suppression, induction of cell cycle inhibition and inhibition of the expression of peroxisome proliferator-activated receptors.
|
30897717 |
2019 |